8 in 8 Series: Biomarker Testing and Neoadjuvant Immunotherapy for Resectable NSCLC

8 in 8: Update on Immunotherapy for Resectable Lung CancerПодробнее

8 in 8 Series: Neoadjuvant Biomarker Trials in Lung CancerПодробнее

Progress in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid TumorsПодробнее

Drs. Altorki & Spicer discuss #NSCLC #Immunotherapy at #ThoracicSummit2022 - https://bit.ly/3BXcsbVПодробнее

Understanding Biomarker Testing in Non-Small Cell Lung CancerПодробнее

NAUTIKA1: targeted therapies in biomarker-selected stage IB-II NSCLCПодробнее

Expert report on neoadjuvant immune checkpoint inhibitors for NSCLCПодробнее

STS Webinar: Biomarker Testing and Neoadjuvant Immunotherapy for Resectable NSCLCПодробнее

Resectable Non-Small Cell Lung CancerПодробнее

Biomarkers in NSCLC - Targeted Therapies in Lung Cancer 2023Подробнее

Gaining Confidence in Predicting and Assessing Response to Cancer ImmunotherapiesПодробнее

Optimizing neoadjuvant therapy in NSCLC with biomarker researchПодробнее

The role of surgery in early-stage NSCLC management | Jessica DoningtonПодробнее

Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLCПодробнее

Everything You Need to Know About Biomarker Testing and Treatment of Genomically Altered NSCLCПодробнее

Molecular Testing and Implications for Adjuvant Therapy in Early Stage NSCLCПодробнее

Challenges associated with biomarker testing for PD-L1 in NSCLCПодробнее

S1 Episode 4: Managing Lung Cancer With Neoadjuvant and Adjuvant TherapyПодробнее